EAM
NKTR icon

Erste Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Erste Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Hold
28,000
– – 0.02% 375
2025
Q4 		$1.2M Buy
28,000
+11,000
+65% +$616K 0.01% 420
2025
Q3 		$1M Buy
+17,000
New +$563K 0.01% 413
2024
Q4 		– Sell
-3,120
Closed -$54.8K – 561
2024
Q3 		$54.8K Hold
3,120
– – ﹤0.01% 510
2024
Q2 		$53.4K Hold
3,120
– – ﹤0.01% 508
2024
Q1 		$41.4K Hold
3,120
– – ﹤0.01% 507
2023
Q4 		$25.8K Hold
3,120
– – ﹤0.01% 527
2023
Q3 		$28.5K Hold
3,120
– – ﹤0.01% 526
2023
Q2 		$27K Hold
3,120
– – ﹤0.01% 553
2023
Q1 		$29.8K Hold
3,120
– – ﹤0.01% 566
2022
Q4 		$103K Hold
3,120
– – ﹤0.01% 531
2022
Q3 		$142K Hold
3,120
– – ﹤0.01% 512
2022
Q2 		$185K Hold
3,120
– – ﹤0.01% 514
2022
Q1 		$261K Hold
3,120
– – 0.01% 493
2021
Q4 		$665K Hold
3,120
– – 0.01% 401
2021
Q3 		$839K Hold
3,120
– – 0.02% 352
2021
Q2 		$815K Hold
3,120
– – 0.02% 363
2021
Q1 		$913K Hold
3,120
– – 0.02% 337
2020
Q4 		$854K Sell
3,120
-733
-19% -$189K 0.02% 349
2020
Q3 		$976K Hold
3,853
– – 0.03% 303
2020
Q2 		$1.3M Hold
3,853
– – 0.05% 274
2020
Q1 		$1.04M Buy
3,853
+1,000
+35% +$309K 0.06% 249
2019
Q4 		$923K Sell
2,853
-314
-10% -$91.1K 0.04% 284
2019
Q3 		$850K Sell
3,167
-5,866
-65% -$2.15M 0.05% 277
2019
Q2 		$4.7M Buy
9,033
+1,313
+17% +$658K 0.25% 107
2019
Q1 		$3.79M Hold
7,720
– – 0.21% 116
2018
Q4 		$3.84M Buy
+7,720
New +$4.66M 0.26% 104

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Erste Asset Management's NKTR Position: Q1 2026 in Review

Erste Asset Management held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 28,000 shares worth $1.83M. The position accounts for 0.02% of the portfolio, ranked #375.

Erste Asset Management first reported a position in NKTR in Q4 2018 and has held it in 27 quarters since. The position peaked at $4.7M in Q2 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Erste Asset Management held 28,000 shares of Nektar Therapeutics worth $1.83M as of Q1 2026.
  • Erste Asset Management left its Nektar Therapeutics share count unchanged in Q1 2026.
  • Nektar Therapeutics made up 0.02% of Erste Asset Management's portfolio in Q1 2026, its #375 holding.
  • Erste Asset Management first reported a position in Nektar Therapeutics in Q4 2018 and has held it in 27 quarters since.
  • Erste Asset Management's Nektar Therapeutics position peaked at $4.7M in Q2 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Erste Asset Management's 13F filing for Q1 2026, filed 11 May 2026.